“…Antibodies, bought or self-established, should prior to utilization be properly examined with respect to sensitivity and specificity for the application planned. The anti-CEA total antibody has been extensively investigated in collaborative epitope screening projects [97,229], and has been subject to studies of differential CEA antibody specificity, and cross-reactivity with other antigens like NCA, and NCA-2 has also been extensively examined [115,230,231]. The T84.66 antibody was shown to be specific for full-length CEA, not recognizing the shorter, C-terminally truncated versions [229].…”